UBS Group
EDSA icon

UBS Group’s Edesa Biotech EDSA Stock Holding History

UBS Group’s Portfolio EDSA Stock Details EDSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55K Buy
6,763
+4,420
+189% +$39.9K ﹤0.01% 7510
2026
Q1 		$12.3K Buy
2,343
+981
+72% +$2.94K ﹤0.01% 8260
2025
Q4 		$1.93K Sell
1,362
-457
-25% -$895 ﹤0.01% 9430
2025
Q3 		$4.49K Buy
1,819
+1,136
+166% +$2.63K ﹤0.01% 8948
2025
Q2 		$1.39K Buy
683
+679
+16,975% +$1.45K ﹤0.01% 9630
2025
Q1 		$10 Sell
4
-27
-87% -$58 ﹤0.01% 10121
2024
Q4 		$52 Buy
31
+27
+675% +$75 ﹤0.01% 9701
2024
Q3 		$18 Hold
4
– – ﹤0.01% 9320
2024
Q2 		$17 Hold
4
– – ﹤0.01% 9321
2024
Q1 		$17 Sell
4
-4,279
-100% -$19.9K ﹤0.01% 9050
2023
Q4 		$19.6K Buy
4,283
+3,506
+451% +$13.3K ﹤0.01% 7118
2023
Q3 		$3.44K Buy
777
+772
+15,440% +$4.56K ﹤0.01% 7560
2023
Q2 		$27 Sell
5
-810
-99% -$5.38K ﹤0.01% 8664
2023
Q1 		$5.2K Buy
815
+810
+16,200% +$8.46K ﹤0.01% 8069
2022
Q4 		$71 Hold
5
– – ﹤0.01% 10442
2022
Q3 		$0 Sell
5
-152
-97% -$1.87K ﹤0.01% 10469
2022
Q2 		$2K Sell
157
-418
-73% -$6.16K ﹤0.01% 9537
2022
Q1 		$12K Buy
575
+172
+43% +$4.76K ﹤0.01% 8166
2021
Q4 		$16K Sell
403
-364
-47% -$17.4K ﹤0.01% 8151
2021
Q3 		$39K Buy
767
+227
+42% +$8.83K ﹤0.01% 6537
2021
Q2 		$20K Buy
540
+535
+10,700% +$21.7K ﹤0.01% 7322
2021
Q1 		$0 Hold
5
– – ﹤0.01% 9091
2020
Q4 		$0 Sell
5
-182
-97% -$7.44K ﹤0.01% 8473
2020
Q3 		$11K Sell
187
-270
-59% -$12.8K ﹤0.01% 6756
2020
Q2 		$16K Buy
457
+309
+209% +$6.96K ﹤0.01% 6691
2020
Q1 		$2K Buy
148
+132
+825% +$2.71K ﹤0.01% 7606
2019
Q4 		$0 Sell
16
-164
-91% -$5.8K ﹤0.01% 8165
2019
Q3 		$8K Buy
180
+42
+30% +$1.52K ﹤0.01% 7274
2019
Q2 		$7K Buy
138
+75
+119% +$3.3K ﹤0.01% 7235
2019
Q1 		$3K Sell
63
-257
-80% -$12.7K ﹤0.01% 7330
2018
Q4 		$12K Buy
320
+238
+290% +$11.1K ﹤0.01% 7136
2018
Q3 		$5K Sell
82
-162
-66% -$10.3K ﹤0.01% 7481
2018
Q2 		$18K Buy
244
+222
+1,009% +$31.8K ﹤0.01% 6766
2018
Q1 		$5K Buy
22
+5
+29% +$1.24K ﹤0.01% 7222
2017
Q4 		$4K Buy
+17
New +$5.41K ﹤0.01% 7460
2017
Q3 		– Sell
-17
Closed -$6.18K – 7776
2017
Q2 		$6K Buy
+17
New +$6.41K ﹤0.01% 7041
2017
Q1 		– Sell
-4
Closed -$2.12K – 7711
2016
Q4 		$2K Sell
4
-9
-69% -$5.54K ﹤0.01% 7501
2016
Q3 		$9K Sell
13
-2
-13% -$1.68K ﹤0.01% 6839
2016
Q2 		$16K Buy
15
+7
+88% +$7.21K ﹤0.01% 6457
2016
Q1 		$12K Hold
8
– – ﹤0.01% 6536
2015
Q4 		$14K Buy
+8
New +$18.6K ﹤0.01% 7055

Other funds holding EDSA

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group's EDSA Position: Q2 2026 in Review

UBS Group increased its Edesa Biotech (EDSA) stake by 189% in Q2 2026, buying an estimated $39.9K and bringing the position to 6,763 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #7510.

UBS Group first reported a position in EDSA in Q4 2015 and has held it in 41 quarters since. 33 funds tracked by Wall St. Rank hold EDSA as of Q2 2026.

  • UBS Group held 6,763 shares of Edesa Biotech worth $55K as of Q2 2026.
  • UBS Group bought 4,420 Edesa Biotech shares in Q2 2026, an estimated $39.9K.
  • Edesa Biotech made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7510 holding.
  • UBS Group first reported a position in Edesa Biotech in Q4 2015 and has held it in 41 quarters since.
  • 33 funds tracked by Wall St. Rank held Edesa Biotech as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.